Renal cell cancer is a type of cancer that affects the kidneys, and treatment options for this condition depend on the stage of the cancer, the patient’s overall health, and other factors. Currently, there are several first-line treatment options available for renal cell cancer, including combinations of targeted therapies and immunotherapies.
One option is the combination of axitinib, a tyrosine kinase inhibitor, and pembrolizumab, a checkpoint inhibitor, which has shown improved overall survival compared to sunitinib in patients with advanced or metastatic renal cell carcinoma. Another combination therapy is cabozantinib, a multikinase inhibitor, plus nivolumab, a checkpoint inhibitor, which has demonstrated improved progression-free survival compared to sunitinib.
In addition, the combination of axitinib and avelumab, a checkpoint inhibitor, has shown favorable overall survival compared to sunitinib. Another option is the combination of atezolizumab, a checkpoint inhibitor, and bevacizumab, an anti-angiogenic agent, which has demonstrated improved progression-free survival compared to sunitinib.
Finally, the COSMIC-313 trial has shown promising results for the triplet regimen of cabozantinib, nivolumab, and ipilimumab in patients with previously untreated advanced or metastatic renal cell carcinoma. These therapies offer a range of options for patients and their healthcare providers to consider when developing a treatment plan.
| Combination Therapy | Mechanism of Action | Clinical Trial Results |
|---|---|---|
| Axitinib + Pembrolizumab | Tyrosine kinase inhibitor + checkpoint inhibitor | Improved overall survival compared to sunitinib in advanced/metastatic RCC |
| Cabozantinib + Nivolumab | Multikinase inhibitor + checkpoint inhibitor | Improved progression-free survival compared to sunitinib |
| Axitinib + Avelumab | Tyrosine kinase inhibitor + checkpoint inhibitor | Favorable overall survival compared to sunitinib |
| Atezolizumab + Bevacizumab | Checkpoint inhibitor + anti-angiogenic agent | Improved progression-free survival compared to sunitinib |
| Cabozantinib + Nivolumab + Ipilimumab | Multikinase inhibitor + checkpoint inhibitor + checkpoint inhibitor | Promising results in previously untreated advanced/metastatic RCC |
Note: These are just some of the first-line treatment options available and are not an exhaustive list. Treatment decisions should be made in consultation with a healthcare provider.
| Combination Therapy | Trade Names |
|---|---|
| Axitinib + Pembrolizumab | Axitinib: Inlyta; Pembrolizumab: Keytruda |
| Cabozantinib + Nivolumab | Cabozantinib: Cabometyx; Nivolumab: Opdivo |
| Axitinib + Avelumab | Axitinib: Inlyta; Avelumab: Bavencio |
| Atezolizumab + Bevacizumab | Atezolizumab: Tecentriq; Bevacizumab: Avastin |
| Cabozantinib + Nivolumab + Ipilimumab | Cabozantinib: Cabometyx; Nivolumab: Opdivo; Ipilimumab: Yervoy |
